{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:50Z","timestamp":1767963710565,"version":"3.49.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"am","delay-in-days":423,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"United Kingdom's Department for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.vaccine.2014.11.049","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T21:02:45Z","timestamp":1417813365000},"page":"954-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children"],"prefix":"10.1016","volume":"33","author":[{"given":"Richard I.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.11.049_bib0005","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1371\/journal.pntd.0000768","article-title":"Etiology of diarrhea in older children, adolescents and adults: a systematic review","volume":"4","author":"Fischer Walker","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0010","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1017\/S0950268810000592","article-title":"Diarrhoea morbidity and mortality in older children, adolescents, and adults","volume":"138","author":"Walker","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0015","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0140-6736(10)60549-1","article-title":"Global, regional, and national causes of child mortality in 2008: a systematic analysis","volume":"375","author":"Black","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0020","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(12)60560-1","article-title":"Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000","volume":"379","author":"Liu","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0025","series-title":"Pneumonia and diarrhea: tackling the deadliest diseases for the world's poorest children","author":"United Nations Children's Fund","year":"2012"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0030","first-page":"197","article-title":"The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000","volume":"81","author":"Kosek","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0035","series-title":"Diarrhoel disease. Fact sheet No. 330","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0040","series-title":"Committing to child survival: promise renewed progress report 2013","author":"United Nations Children's Fund","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0045","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4269\/ajtmh.2002.66.590","article-title":"Early childhood diarrhea is associated with diminished cognitive function 4\u20137 years later in children in a northeast Brazilian shantytown","volume":"66","author":"Niehaus","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0188-4409(02)00379-X","article-title":"Magnitude and impact of diarrheal diseases","volume":"33","author":"Guerrant","year":"2002","journal-title":"Arch Med Res"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1471-4922(02)02253-5","article-title":"Updating the DALYs for diarrhoeal disease","volume":"18","author":"Guerrant","year":"2002","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1753-4887.2008.00082.x","article-title":"Malnutrition as an enteric infectious disease with long-term effects on child development","volume":"66","author":"Guerrant","year":"2008","journal-title":"Nutr Rev"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0065","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/ije\/dyh335","article-title":"Comorbidity in childhood in northern Ghana: magnitude, associated factors, and impact on mortality","volume":"34","author":"Fenn","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case\u2013control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0075","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1586\/14760584.3.5.585","article-title":"Enterotoxigenic Escherichia coli virulence factors and vaccine approaches","volume":"3","author":"Sizemore","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1128\/iai.38.1.74-79.1982","article-title":"Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens","volume":"38","author":"Ahren","year":"1982","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.10.4.569","article-title":"Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli","volume":"10","author":"Wolf","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0090","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/CVI.05342-11","volume":"18","author":"Harro","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0095","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1128\/CVI.00364-12","article-title":"The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease","volume":"19","author":"Darsley","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0100","series-title":"Evaluation of a lyophilized formulation of enterotoxigenic Escherichia coli (ETEC) ACE527 vaccine administered alone or with a double-mutant E. coli heat-labile toxin (dmLT) in healthy adult subjects","author":"Harro","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0105","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1016\/j.vaccine.2006.02.052","article-title":"Expression of enterotoxigenic Escherichia coli colonization factors in Vibrio cholerae","volume":"24","author":"Favre","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0110","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/j.vaccine.2006.12.028","article-title":"Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease","volume":"25","author":"Walker","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0115","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/S0264-410X(00)00006-2","article-title":"Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area","volume":"18","author":"Richie","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0120","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0264-410X(02)00611-4","article-title":"Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains","volume":"21","author":"Barry","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0125","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1016\/j.vaccine.2005.07.013","article-title":"Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model","volume":"24","author":"Barry","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrgastro.2013.12","article-title":"Progress and pitfalls in Shigella vaccine research","volume":"10","author":"Barry","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0135","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1128\/IAI.05814-11","article-title":"Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit","volume":"79","author":"Wu","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0140","series-title":"Highly efficient antigen expression for combined Shigella-ETEC vaccine development","author":"Barry","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0145","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/IAI.73.1.258-267.2005","article-title":"Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI\/LTB) that express antigens from enterotoxigenic Escherichia coli","volume":"73","author":"Ranallo","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0150","series-title":"Development of a novel oral typhoid-ETEC vaccine","author":"Cranenberg","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0155","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2007.03.034","article-title":"Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico","volume":"25","author":"Sack","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0160","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00006454-200204000-00012","article-title":"Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants","volume":"21","author":"Savarino","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0165","series-title":"Efficacy of an oral, inactivated whole-cell enterotoxigenic E. coli\/cholera toxin B subunit vaccine in Egyptian infants","author":"Savarino","year":"2003"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0170","first-page":"97","article-title":"Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries","volume":"81","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0175","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.vaccine.2013.03.027","volume":"31","author":"Holmgren","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0180","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.vaccine.2012.12.063","article-title":"Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA\/I overexpressing bacteria and recombinantly produced LTB\/CTB hybrid protein","volume":"31","author":"Lundgren","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0185","series-title":"Excellent safety and immunogenicity of a complete tetravalent oral inactivated whole cell ETEC vaccine tested with and without dmLT adjuvant demonstrated in a placebo-controlled Phase I study","author":"Lundgren","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0190","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/0140-6736(90)91013-Z","article-title":"Modern vaccines: enteric infections","volume":"335","author":"Levine","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0195","series-title":"New generation vaccines","article-title":"Vaccines against enterotoxigenic Escherichia coli infections","author":"Levine","year":"1990"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1473-3099(13)70297-4","article-title":"Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers\u2019 diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala","volume":"14","author":"Behrens","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0205","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/CVI.00464-13","article-title":"Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli","volume":"20","author":"El-Kamary","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0210","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.vaccine.2007.01.043","article-title":"Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study","volume":"25","author":"McKenzie","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1473-3099(13)70297-4","article-title":"Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers\u2019 diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala","volume":"14","author":"Behrens","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0220","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/158.2.372","article-title":"Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial","volume":"158","author":"Clemens","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0225","series-title":"Rational design of a vaccine against the heat-stable toxin of enterotoxigenic Escherichia coli","author":"Puntervoll","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0230","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/erv.12.37","article-title":"Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans","volume":"11","author":"Zhang","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0235","series-title":"Heat-stable (STa) toxoids of enterotoxigenic Escherichia coli for toxoid fusions with double mutant heat-labile toxin (dmLT) elicit neutralizing anti-STa antibodies","author":"Ruan","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0240","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/IAI.01749-14","article-title":"Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin","volume":"82","author":"Taxt","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0245","series-title":"A genetic fusion elicits antibodies inhibiting adherence of E. coli expressing CFA\/I, CFA\/II, and CFA\/IV and neutralizing both LT and STa enterotoxin","author":"Zhang","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0250","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1128\/IAI.72.12.7190-7201.2004","article-title":"Evolutionary and functional relationships of colonization factor antigen I and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli","volume":"72","author":"Anantha","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0255","series-title":"Advancement of an adhesin-based enterotoxigenic E. coli vaccine into clinical evaluation","author":"Savarino","year":"2011"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0260","series-title":"Phase 1 clinical evaluation of adhesin-based ETEC vaccines","author":"Gutierrez","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0265","series-title":"Evaluation of memory B cell generation following skin vaccination with enterotoxigenic E. coli CFA\/I+ tip adhesin protein CfaE, or adhesin-toxin chimera, CfaE-sCTA2\/LTB5 admixed with the adjuvant LTR192G","author":"Laird","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0270","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1586\/14760584.2014.905745","article-title":"Novel antigens for enterotoxigenic Escherichia coli vaccines","volume":"13","author":"Fleckenstein","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0275","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1172\/JCI117991","article-title":"Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro","volume":"95","author":"Fasano","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0280","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1574-695X.2011.00778.x","article-title":"Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells","volume":"61","author":"Farfan","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0285","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/424680","article-title":"Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208","volume":"190","author":"Kotloff","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0290","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1128\/CMR.00032-07","article-title":"Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion","volume":"21","author":"Schroeder","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/erv.12.135","article-title":"Recent progress towards development of a Shigella vaccine","volume":"12","author":"Camacho","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0300","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/IAI.67.2.782-788.1999","article-title":"Strategy for cross-protection among Shigella flexneri serotypes","volume":"67","author":"Noriega","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0305","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0310","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1128\/iai.64.8.3055-3061.1996","article-title":"Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine","volume":"64","author":"Noriega","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0315","series-title":"Phase 1 and 2 trials of CVD1208S, a live, oral guaBA, sen, set Shigella flexneri 2a vaccine","author":"Kotloff","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0320","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1073\/pnas.86.10.3867","article-title":"Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin","volume":"86","author":"Bernardini","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0325","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1128\/iai.64.4.1190-1196.1996","article-title":"Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier","volume":"64","author":"Barzu","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0330","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"Coster","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0335","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2010.10.035","article-title":"Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh","volume":"29","author":"Rahman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0340","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/14760584.5.5.669","article-title":"Live-attenuated Shigella vaccines","volume":"5","author":"Venkatesan","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0345","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.4049\/jimmunol.168.10.5240","article-title":"Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium","volume":"168","author":"d\u2019Hauteville","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0350","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/IAI.00533-09","article-title":"Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants","volume":"78","author":"Ranallo","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0355","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1016\/j.vaccine.2011.04.115","article-title":"Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection","volume":"29","author":"Barnoy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0360","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/131.5.553","article-title":"Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine","volume":"131","author":"Germanier","year":"1975","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0365","doi-asserted-by":"crossref","DOI":"10.1128\/genomeA.00650-13","article-title":"Genome sequence of Salmonella enterica serovar Typhi oral vaccine strain Ty21a","volume":"1","author":"Xu","year":"2013","journal-title":"Genome Announc"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0370","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/iai.34.3.746-750.1981","article-title":"Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain","volume":"34","author":"Formal","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0375","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijmm.2013.01.001","article-title":"Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a","volume":"303","author":"Dharmasena","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0380","series-title":"Temperature-stabilized, acid-resistant Ty21a-vectored oral enteric fever-shigellosis vaccine \u2013 advances in development","author":"Kopecko","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0385","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.vaccine.2005.07.014","article-title":"Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial","volume":"24","author":"McKenzie","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0390","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.vaccine.2006.11.012","article-title":"Vaccine potential for inactivated shigellae","volume":"25","author":"Osorio","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0395","series-title":"A phase 1 study to evaluate the safety, tolerability, and immunogenicity of an oral inactivated whole cell Shigella flexneri 2a vaccine in healthy adult subjects","author":"Harro","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0400","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0405","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1128\/iai.59.12.4450-4458.1991","article-title":"Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid","volume":"59","author":"Chu","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0410","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1- to 4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0415","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1039\/B400986J","article-title":"Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease","volume":"2","author":"Wright","year":"2004","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0420","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.4049\/jimmunol.176.3.1686","article-title":"Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine","volume":"176","author":"Phalipon","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0425","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1073\/pnas.0500044102","article-title":"Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli","volume":"102","author":"Feldman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0430","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1073\/pnas.0509207103","article-title":"Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems","volume":"103","author":"Wacker","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1475-2859-9-61","article-title":"Production of glycoprotein vaccines in Escherichia coli","volume":"9","author":"Ihssen","year":"2010","journal-title":"Microb Cell Fact"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0440","series-title":"Clinical evaluation of a novel bioconjugate vaccine against Shigella dysenteriae 01: a step towards a universal Shigella vaccine","author":"Wacker","year":"2009"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0445","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1128\/IAI.68.12.6624-6632.2000","article-title":"Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine","volume":"68","author":"Turbyfill","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0450","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1586\/erv.09.127","article-title":"Inactivated and subunit vaccines to prevent shigellosis","volume":"8","author":"Kaminski","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0455","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/CVI.00435-08","article-title":"Mucosal adjuvanticity of a Shigella invasin complex with DNA-based vaccines","volume":"16","author":"Kaminski","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0460","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.vaccine.2005.11.040","article-title":"Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine","volume":"24","author":"Oaks","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0465","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2011.07.033","article-title":"Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine","volume":"29","author":"Riddle","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0470","series-title":"Shigella flexneri 2a Invaplex vaccine: update on recent phase 1 and phase 2b clinical studies","author":"Harro","year":"2009"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0475","series-title":"Protection against Shigella in mice by a novel approach using outer membrane particles","author":"Gerke","year":"2011"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0480","doi-asserted-by":"crossref","first-page":"e35616","DOI":"10.1371\/journal.pone.0035616","article-title":"High yield production process for Shigella outer membrane particles","volume":"7","author":"Berlanda","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0485","series-title":"A Shigella sonnei vaccine based on generalized modules for membrane antigens: towards proof-of-concept for a novel vaccine platform","author":"Gerke","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0490","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/166.1.158","article-title":"Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of Shigella species in Chilean and North American populations","volume":"166","author":"Van de Verg","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0495","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/jcm.31.2.454-457.1993","article-title":"Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients","volume":"31","author":"Cam","year":"1993","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0500","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/IAI.06174-11","article-title":"Broadly protective Shigella vaccine based on type III secretion apparatus proteins","volume":"80","author":"Martinez-Becerra","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0505","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0510","series-title":"Intradermal vaccination with Shigella IpaB and IpaD type III secretion proteins adjuvanted with an E. coli enterotoxin mutant elicit robust protective immunity against serotypes","author":"Pasetti","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0515","series-title":"Protective capacity of an IpaB\/IpaD fusion protein against Shigella","author":"Picking","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0520","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1016\/j.vaccine.2011.08.121","article-title":"Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice","volume":"29","author":"Camacho","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0525","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1128\/CVI.00164-10","article-title":"Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation","volume":"17","author":"Tamayo","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0530","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1016\/j.vaccine.2013.05.020","article-title":"Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice","volume":"31","author":"Camacho","year":"2013","journal-title":"Vaccine"},{"issue":"54","key":"10.1016\/j.vaccine.2014.11.049_bib0535","first-page":"12","article-title":"Pan-Shigella Surface Protein antigen 1 as potential cross-protective antigen for Shigella vaccine development","volume":"190","author":"Kim","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0540","doi-asserted-by":"crossref","first-page":"e22663","DOI":"10.1371\/journal.pone.0022663","article-title":"Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model","volume":"6","author":"Pore","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0545","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/j.vaccine.2009.07.054","article-title":"Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a","volume":"27","author":"Pore","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0550","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.vaccine.2013.05.100","article-title":"Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate","volume":"31","author":"Pore","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0555","series-title":"Potential health impact and market demand for Shigella and ETEC vaccines","author":"Pelkowski","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0560","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1128\/IAI.00139-07","article-title":"Identification of a Campylobacter jejuni protein that cross-reacts with cholera toxin","volume":"75","author":"Albert","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0565","doi-asserted-by":"crossref","first-page":"e00246","DOI":"10.1128\/mBio.00246-13","article-title":"Oral immunization with cholera toxin provides protection against Campylobacter jejuni in an adult mouse intestinal colonization model","volume":"4","author":"Albert","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0570","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1128\/CVI.00255-10","article-title":"Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model","volume":"17","author":"Islam","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0575","first-page":"207","article-title":"Cross-reactivity of outer membrane proteins of Campylobacter species with cholera toxin","volume":"133","author":"Albert","year":"2011","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0580","series-title":"Vaccination of travelers to Guatemala (GU) and Mexico (MX) with an oral killed vaccine (OKV) for enterotoxigenic E. coli (ETEC): impact of vaccine \u201ctake\u201d on risk of ETEC disease and infection with enteric pathogens","author":"Bourgeois","year":"2007"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0585","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1586\/14760584.7.5.561","article-title":"Vaccination with Dukoral against travelers\u2019 diarrhea (ETEC) and cholera","volume":"7","author":"Jelinek","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0590","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mi.2012.56","article-title":"Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses","volume":"6","author":"Bergqvist","year":"2013","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0595","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/infdis\/157.2.374","article-title":"Five-year immunologic memory in Swedish volunteers after oral cholera vaccination","volume":"157","author":"Jertborn","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0600","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/0264-410X(94)90176-7","article-title":"Immunological memory after immunization with oral cholera B subunit \u2013 whole-cell vaccine in Swedish volunteers","volume":"12","author":"Jertborn","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0605","series-title":"Old Herborn University Seminar Monograph 24","first-page":"17","article-title":"Determinants of responsiveness to oral vaccines in developing countries","author":"Sack","year":"2010"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0610","series-title":"Old Herborn University Seminar Monograph 24","first-page":"95","article-title":"Effects of malnutrition and micronutrient deficiency on hypo-responsiveness to oral vaccines: what can be done to overcome this?","author":"Qadri","year":"2010"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0615","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/iai.63.5.1617-1623.1995","article-title":"Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity","volume":"63","author":"Dickinson","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0620","doi-asserted-by":"crossref","first-page":"8598","DOI":"10.1016\/j.vaccine.2007.09.073","article-title":"Sublingual immunization induces broad-based systemic and mucosal immune responses in mice","volume":"25","author":"Cuburu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0625","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4161\/hv.7.1.13739","article-title":"Sublingual vaccination","volume":"7","author":"Czerkinsky","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2014.11.049_bib0630","series-title":"The case for investment in enterotoxigenic Escherichia coli vaccines","author":"PATH","year":"2011"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14016065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14016065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:21:35Z","timestamp":1759400495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14016065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":126,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0264410X14016065"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}